

Development of Rat Natriuretic Peptide Biomarker Assays

Heart failure (HF) is a clinical syndrome associated with progressive cardiac, vascular, and renal dysfunction that affects more than 23 million people annually worldwide. Despite medical advances, an aging population and new therapies that prolong the lives of diagnosed patients continue to increase the prevalence of HF. Early identification of susceptible persons may save lives and ultimately reduce the overall prevalence of the disease.


The measurement of protein biomarkers presents possible solutions for screening, diagnosis, prognosis, and therapeutic management of the disease with downstream benefits of improved clinical decision making and more effective patient care. Natriuretic peptides have been identified as potential biomarkers for cardiac injury that precedes heart failure for their role in vasodilation, anti-inflammation, and natriuresis. In particular, it has been demonstrated that BNP and NT-proBNP levels can facilitate diagnosis and guide HF therapy. Additionally, BNP and NT-proBNP were recently shown to be useful cardiac injury markers for risk assessment in non-Hodgkin lymphoma patients treated with chemotherapy.

Meso Scale Discovery[®] (MSD) has developed and characterized immuno-assays for 3 rat natriuretic peptide biomarkers (BNP, NT-proBNP, and NT-proANP). These assays offer high sensitivity, reduced sample volume, and wide dynamic range. Collectively, these advantages enable endogenous and elevated levels to be measured at a single dilution factor and provide improved assay throughput (over ELISA and bead-based assays).



Description of Markers


- Natriuretic peptides play a key role in antagonizing the actions of the renin-angiotensin-aldosterone system, thus promoting vasodilatation and natriuresis. Natriuretic peptides include 4 family members that share a common 17-amino acid ring structure.
 - ANP: Atrial natriuretic peptide, 28 amino acids
 - BNP: Brain natriuretic peptide, 32 amino acids
 - CNP: C-type natriuretic pepide, 22 amino acids
 - DNP: Dendroaspis natriuretic peptide



Natriuretic peptides are produced as prohormones and cleaved to active (ANP/BNP) and inactive NT forms (NT-proANP/NT-proBNP).

ANP Transcription and Translation

BNP Transcription and Translation



• Elevated levels of ANP/BNP have been associated with heart failure, systemic and pulmonary hypertension, hypertrophic and restrictive cardiomyopathy, pulmonary embolism, COPD, cor pulmonale, AMI cirrhosis, and renal failure.

The MSD[®] Platform

MSD's electrochemiluminescence detection technology uses SULFO-TAG[™] labels that emit light upon electrochemical stimulation initiated at the electrode surfaces of MULTI-ARRAY[®] and MULTI-SPOT[®] microplates.




Electrochemiluminescence Features:

- Minimal non-specific backgrounds and strong signal responses to analyte yield high signal to background ratios
- The stimulation mechanism (electricity) is decoupled from the response (light signal)
- Proximity assay only labels bound near the electrode surface are excited, enabling non-washed assays
- Flexibility labels are stable, non-radioactive, and directly conjugated to biological molecules

- Emission at ~620 nm eliminating problems with color quenching
- Signal amplification multiple rounds of excitation and emission of each label enhance light levels and improve sensitivity
- Carbon electrode surface has 10X greater binding capacity than polystyrene well
- Surface coatings can be customized



Standard Curve



BNP						
Concentration (pg/mL)	Average Signal	% CV				
0	79	5.2				
2.74	138	4.3				
8.23	271	3.8				
24.7	620	3.3				
74.1	1692	4.5				
222	5187	4.6				
667	17085	4.3				

63192

NT-proANP

Concentration

(pg/mL)

0

24.4

97.7

391

1563

6250

Average

Signal

89

300

2321

31406

249481

811537

4.1

% CV

8.2

12.4

6.6

4.5

5.8

3.0

6.0

5.3

Protocol:

- 1 Add 150 µL blocking solution. Incubate for 1 hour at RT.
- 2 Wash with PBS-T. Add 25 μL of capture antibody, Incubate for 1 hour at RT.
- 3 Wash with PBS-T. Add 25 μL of standard or diluted sample. Incubate for 2 hours at RT.
- 4~ Wash with PBS-T. Add 25 μL of detection antibody. Incubate for 2 hours at RT.
- 5 Wash with PBS-T. Add 150 μL of Read Buffer T and then read on a SECTOR $^{\otimes}$ Imager.

Protocol:

- 1 Add 25 µL Diluent 30. Incubate for 30 min at RT.
- 2 Wash with PBS-T. Add 25 μL of standard or sample. Incubate for 2 hours at RT.
- 3 Wash with PBS-T. Add 25 μL of detection antibody. Incubate for 2 hours at RT.
- 4~ Wash with PBS-T. Add 150 μL of Read Buffer T and then read on a SECTOR $^{\otimes}$ Imager.

NT	-proBNP	
Concentration (pg/mL)	Average Signal	% CV
0	146	7.7
1.10	184	4.8
4.30	315	3.1
17.4	782	5.3
69.5	2708	5.2
278	11300	5.1
1111	51081	4.0
4445	223091	3.9

Protocol

- Wash the plate with PBS-T. Add 25 µL assay diluent followed by 25 µL standard or sample. Incubate for1 hour at RT.
- 2 Wash with PBS-T. Add 25 μL of detection antibody. Incubate for 2 hours at RT.
- 3 Wash with PBS-T. Add 150 μL of Read Buffer T and then read on a SECTOR $^{\otimes}$ Imager.

Assay Sensitivity

1000

100

0.1

10

100

Concentration [pg/mL]

A multi-plate, multi-day study was performed to measure the reproducibility of the assay. The lower limit of quantitation (LLOQ) and upper limit of quantitation (ULOQ) were proposed from the multiple plate run and determined as the standard point where the % CV of the calculated concentration was less than 20% and the percent recovery of the standard was between 80% and 120%.

1000 10000

 BNP
 NT-proANP
 NT-proBNP

 LLOD (pg/mL)
 1.47
 142
 0.817

 Proposed LLOQ (pg/mL)
 10.0
 400
 5.0

 Proposed ULOQ (pg/mL)
 800
 100000
 4000

The lower limit of detection (LLOD) is the calculated concentration of the signal that is 2.5 standard deviations over the blank (zero calibrator).



Precision: Multi-Day Study

The controls were made by spiking calibrators into rat EDTA plasma and tested in triplicate or quadruplicate on each of 9 plates across multiple days (n>3). Average Intra-plate % CV is the average % CV of the control replicates within an individual plate. Inter-plate % CV is the variability of controls across 9 plates over 3 days.

	Control	Plates	Average Conc. (pg/mL)	Average Intra-plate % CV	Inter-plate % CV
	High	9	425	3.6	7.6
BNP	Mid	9	75.9	2.7	7.0
	Low	9	24.0	4.0	9.0
	High	9	2268	4.6	7.4
NT-proBNP	Mid	9	243	3.7	6.6
	Low	9	18.4	4.2	15

Spike Recovery

Rat EDTA and heparin plasma samples were spiked with calibrator at multiple values throughout the range of the assay. Results of spike recovery may vary based on the individual samples.

% Recovery = measured / expected x 100

		BN	۱P	
Samples	Spike Conc. (pg/mL)	Measured Conc. (pg/mL)	Measured Conc. % CV	% Recovery
50.71	800	811	2.7	100
EDTA	400	429	2.2	105
Plasma 1	200	211	1.5	102
	100	119	2.2	110
	0	7.78		
	800	881	1.9	107
EDTA	400	428	11.3	100
Plasma 2	200	231	8.0	102
	100	131	1.4	104
	0	26.4		
	800	932	1.0	108
EDTA	400	478	8.9	103
Plasma 3	200	260	7.1	98
	100	165	5.1	100
	0	64.7		
	800	846	0.6	106
Heparin	400	387	3.3	97
Plasma	200	194	9.1	97
	100	105	10.3	104
	0	1.07		

	NT-proANP					
Samples	Spike Conc. (pg/mL)	Measured Conc. (pg/mL)	Measured Conc. % CV	% Recovery		
	50000	54774	3.7	99		
EDTA	12500	19270	5.8	108		
Plasma	3130	9172	1.2	109		
	0	5289				
	50000	48806	1.9	87		
Heparin	12500	18098	0.7	98		
Plasma	3130	9206	2.0	101		
- aona	0	5957				

	NT-proBNP					
Samples	Spike Conc. (pg/mL)	Measured Conc. (pg/mL)	Measured Conc. % CV	% Recovery		
	4000	4023	1.8	100		
FDT 4	1000	1036	2.6	102		
EDTA	250	281	1.1	105		
Plasma	62.5	83.0	2.4	106		
	15.6	33.6	1.2	109		
	0	15.6				
	4000	3777	1.1	94		
	1000	991	4.3	98		
Heparin	250	269	1.5	103		
Plasma	62.5	77.2	4.8	104		
	15.6	30.0	3.3	110		
	0	11.9				

Dilution Linearity

Rat EDTA and heparin plasma were tested and data are shown below. The concentrations shown below have been corrected for dilution (concentration = measured x dilution factor). Percent recovery is calculated as the measured concentration divided by the concentration of the previous dilution (expected). % Recovery = (measured x dilution factor) / expected x 100.

	BNP					
Samples	Fold Dilution	Conc. (pg/mL)	Conc. % CV	% Recovery		
	Neat	701	10.4			
	2	650	9.1	93		
	4	589	5.9	91		
EDTA	8	575	3.1	98		
Plasma	16	581	1.3	101		
	32	589	2.3	101		
	64	< LLOQ	17.2	97		
	128	< LLOQ	-	-		
	Neat	561	6.3			
	2	558	10.6	99		
	4	553	8.3	99		
Heparin	8	542	3.0	98		
Plasma	16	537	1.6	99		
	32	569	5.8	106		
	64	552	3.6	97		
	128	< LLOQ		-		

Samples	NT-proANP					
	Fold Dilution	Conc. (pg/mL)	Conc. % CV	% Recovery		
	Neat	21343	4.7			
	2	23213	0.3	109		
EDTA	4	24628	0.2	106		
Plasma	8	25194	0.5	102		
	16	25703	2.3	102		
	Neat	8432	4.5			
Heparin P l asma	2	9498	6.1	113		
	4	10515	2.0	111		
ridsilla	8	12822	2.3	122		
	16	16322	4.6	127		

	NT-proBNP					
Samples	Fold Dilution	Conc. (pg/mL)	Conc. % CV	% Recovery		
	2	96.8	5.6			
	5	78	3.6	81		
EDTA	10	< LLOQ	-	-		
Plasma	20	< LLOQ	-	-		
	40	< LLOQ	-	-		
	2	137.9	5.7			
Heparin P l asma	5	108.6	0.9	79		
	10	127.4	4.2	117		
rasilid	20	< LLOQ	-	-		
	40	< LLOQ	-	-		



Samples

Rat samples were assayed for NT-proBNP, BNP, and NT-proANP. Samples were measured neat for NT-proBNP, but were diluted at 1:2 for BNP and NT-proANP measurement. Concentrations in gray were below proposed LLOQ for the analyte designated.

			BN		
Samples	Fold Dilution	Average Signa l	% CV	Calc. Conc. (pg/mL)	Measured Conc. % CV
Serum-1	2	100	4.2	2.21	22.6
Serum - 2	2	103	1.4	2.56	6.5
Serum - 3	2	101	3.5	2.27	18.3
Serum -4	2	99	7.1	2.09	39.8
EDTA plasma-1	2	308	10.8	25.4	14.3
EDTA plasma-2	2	283	7.8	22.7	10.6
EDTA plasma-3	2	157	10.8	8.74	21.9
Heparin plasma-1	2	113	0	3.73	0
Heparin plasma-2	2	170	0	10.2	0

		NT-proANP			
Samples	Fold Dilution	Average Signa l	% CV	Calc. Conc. (pg/mL)	Measured Conc. % CV
Serum-1	2	17567	7.1	21502	4.4
Serum -2	2	20474	4.3	23678	2.7
Serum - 3	2	35699	2.8	34099	1.9
Serum -4	2	14730	2.3	19281	1.4
EDTA plasma-1	2	18305	1.6	22067	1.0
EDTA plasma-2	2	20264	8.8	23518	5.6
EDTA plasma-3	2	40687	1.8	37342	1.3
Heparin plasma-1	2	22853	9.0	25389	5.7
Heparin plasma-2	2	16214	10.8	20449	6.7

	NT-proBNP				
Samples	Fold Dilution	Average Signa l	% CV	Calc. Conc. (pg/mL)	Measured Conc. % CV
Serum-1	Neat	387	0.7	6.8	1.1
Serum-2	Neat	199	5.7	1.9	16.6
Serum-3	Neat	144	3.4	0.3	50.3
Serum-4	Neat	168	1.3	1.0	6.0
Serum-5	Neat	340	9.4	5.6	14.8
Serum-6	Neat	383	5.0	6.7	7.3
Serum-7	Neat	505	5.5	9.8	7.1
Serum-8	Neat	256	2.2	3.4	4.4
EDTA plasma-1	Neat	5717	3.5	130	3.4
EDTA plasma-2	Neat	2487	2.5	57.1	2.5
EDTA plasma-3	Neat	1366	2.3	30.8	2.5
EDTA plasma-4	Neat	1897	0.6	43.4	0.6
EDTA plasma-5	Neat	2474	3.3	56.8	3.3
EDTA plasma-6	Neat	1728	15.7	39.4	16.2
EDTA plasma-7	Neat	3,941	14.7	90.2	14.5
EDTA plasma-8	Neat	2,037	7.4	46.6	7.5
Heparin plasma-1	Neat	5816	2.5	132	2.5
Heparin plasma-2	Neat	1970	5.0	45.1	5.1
Heparin plasma-3	Neat	889	2.9	19.3	3.2
Heparin plasma-4	Neat	874	0.2	19.0	0.3
Heparin plasma-5	Neat	2712	8.1	62.3	8.1
Heparin plasma-6	Neat	1679	8.8	38.3	9.2
Heparin plasma-7	Neat	2856	24.6	65.5	24.6
Heparin plasma-8	Neat	1918	2.5	43.9	2.6

Specificity

In order to assess assay specificity, NT-proANP, BNP, and NT-proBNP assays were run with single NT-proANP, BNP, and NT-proBNP calibrators and single detection antibodies. The table below shows the % cross-reactivity for each individual detection antibody.

	% Cross-Reactivity	
Assay	BNP calibrator	NT-proBNP calibrator
BNP	100	<0.1
NT-proBNP	<0.1	100
NT-proANP	<0.1	<0.1

Conclusions

Biomarker measurement is emerging as a powerful tool for diagnosis, prognostic stratification, and administration of personalize medical treatment. MSD has developed ultra-sensitive assays to measure rat natriuretic peptides to support research into the pathophysiology of heart failure. Through diligent characterization, the following advantages have been verified:

- Simple protocols that require minimal sample volumes
- Peptide specificity (no cross-reactivity between the peptides)
- Wide dynamic range
- High precision (average intra-plate % CV<5 and average inter-plate % CV <10)